Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.89)
# 3,235
Out of 5,132 analysts
119
Total ratings
28.18%
Success rate
-4.15%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $4.95 | +162.63% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $21.97 | +45.65% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $3.73 | +141.29% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $87.71 | +8.32% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $15.33 | +63.08% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $5.12 | +134.38% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $8.27 | +45.10% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $3.29 | +113.09% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.33 | +50.38% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $15.05 | +12.96% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.28 | +294.74% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $18.91 | +143.26% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.05 | +661.90% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $33.24 | -27.80% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.24 | +78.57% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.71 | +57.62% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.16 | +404.81% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.43 | +261.17% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.71 | +104.68% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.23 | +1,002.78% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.80 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $10.45 | +2,371.77% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $4.95
Upside: +162.63%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $21.97
Upside: +45.65%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $3.73
Upside: +141.29%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $87.71
Upside: +8.32%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.33
Upside: +63.08%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $5.12
Upside: +134.38%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $8.27
Upside: +45.10%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.29
Upside: +113.09%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.33
Upside: +50.38%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $15.05
Upside: +12.96%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.28
Upside: +294.74%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $18.91
Upside: +143.26%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.05
Upside: +661.90%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $33.24
Upside: -27.80%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.24
Upside: +78.57%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $5.71
Upside: +57.62%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.16
Upside: +404.81%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.43
Upside: +261.17%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.71
Upside: +104.68%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.23
Upside: +1,002.78%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.80
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $10.45
Upside: +2,371.77%